press releases

Date Title Teaser
12/09/19
Summary Togglebluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18 CAMBRIDGE, Mass. , & PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 9, 2019-- bluebird bio, Inc.
12/09/19
Summary Togglebluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin™ Gene Therapy for β-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition More than four years of durable transfusion independence (TI), stable total hemoglobin (Hb) levels and reduced liver iron concentrations in completed Phase 1/2 Northstar (HGB-204) study in patients who do not have a β 0 / β 0 genotype Ninety percent of evaluable patients who do not have a β 0 / β 0
12/07/19
Summary Togglebluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition 99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at up to 21 months post-treatment Group C patients at six months post-treatment
12/06/19
Summary ToggleBristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Study met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population Safety results are consistent with the data presented in CRB-401 study PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec.
12/02/19
Summary Togglebluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 2, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61 st American Society of Hematology Annual Meeting and Exposition.
11/12/19
Summary Togglebluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy CAMBRIDGE, Mass. & MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning
11/06/19
Summary Togglebluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin™ gene therapy for patients with sickle cell disease New data from ongoing Phase 3 studies of LentiGlobin™
10/31/19
Summary Togglebluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress - Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined commercial manufacturing process - - Ended quarter with $1.41 billion in cash, cash
10/23/19
Summary Togglebluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that Jeffrey T. Walsh , chief strategy officer, has decided to transition from his current role effective January 6, 2020 . “On behalf of bluebird, we are grateful for all that Jeff has
10/22/19
Summary ToggleEuropean Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™ First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β 0 /β 0 genotype now available to be manufactured in the European Union CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2019-- bluebird bio, Inc.
10/09/19
Summary Togglebluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases   CAMBRIDGE, Mass. and BAGSVÆRD, Denmark --(BUSINESS WIRE)--Oct. 9, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome   editing treatments for genetic diseases,
09/27/19
Summary Togglebluebird bio Appoints William R. Sellers, M.D. to Board of Directors   CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed William R. Sellers , M.D. to its Board of Directors. “I’m excited to welcome Bill to the Board to help navigate an important stage in bluebird’s evolution,” said Nick
09/18/19
Summary Togglebluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 18, 2019-- bluebird bio, Inc.
09/03/19
Summary Togglebluebird bio to Present Data from Clinical Development Program of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress Data Include Updates from Phase 2/3 Starbeam Study (ALD-102) of Lenti-D for CALD and Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) announced that updated data from
08/22/19
Summary Togglebluebird bio Announces Investor Events in September CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 22, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14 th Annual Biotech Conference , Wednesday, September 4 , at 8:00 a.m.
08/01/19
Summary Togglebluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress – Received EU conditional marketing authorization for ZYNTEGLO ® (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion dependent β-thalassemia (TDT) who do not have a β 0 /β 0 genotype – – Presented data across LentiGlobin® for TDT and
06/14/19
Summary Togglebluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress Up to 3.8 years of transfusion independence in Phase 1/2 Northstar (HGB-204) study in patients with TDT who do not have a β 0 /β 0 genotype Four of five evaluable patients achieved transfusion independence in ongoing Phase 3 Northstar-2 (HGB-207) study of patients with TDT who do not have a β 0 /β
06/14/19
Summary Togglebluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb At up to 15 months post-treatment with LentiGlobin, there were no reports of serious vaso-occlusive crisis or acute chest
06/06/19
Summary Togglebluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting, and to discuss the approval of ZYNTEGLO ® (autologous CD34+ cells
06/03/19
Summary Togglebluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT) European marketing authorization for ZYNTEGLO follows the fastest assessment of an advanced therapy medicinal product (ATMP) as part of the European Medicines Agency’s Priority Medicines (PRIME) program
05/31/19
Summary Togglebluebird bio Announces Investor Events in June CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 31, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Company will hold a conference call to discuss data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 14 at 8:00 am ET .
05/16/19
Summary Togglebluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT New data from ongoing Phase 3 Northstar-2 (HGB-207) study of LentiGlobin for TDT in patients who do not have β 0 /β 0 genotype and Phase 3 Northstar-3 (HGB-212) of patients
05/09/19
Summary Togglebluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies New Collaboration with Seattle Children’s Research Institute Targets New Immunotherapy Approaches to Acute Myeloid Leukemia Phase 1/2 Study for Merkel Cell Carcinoma Planned with Fred Hutchinson Cancer Research Center Additional Preclinical Programs Across Both the Severe Genetic Disease and
05/03/19
Summary Togglebluebird bio Announces Investor Events in May CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Company will host an Analyst Day, Thursday, May 9 , at 8:30 am ET at The Maxwell Hotel NYC , New York, NY . In addition, members of the management team will present at the Bank of America
05/02/19
Summary Togglebluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress – Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have β 0 /β 0 genotype – – Company hosting Analyst Day on May 9, 2019 focused on
05/01/19
Summary ToggleCelgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2019-- Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies’
05/01/19
Summary Togglebluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2019-- bluebird bio, Inc. (Nasdaq: BLUE), has appointed Joanne Smith-Farrell , Ph.D., to chief business officer. In this role, Joanne will lead corporate development and strategy, and she will also continue to serve as our oncology franchise leader.
03/29/19
Summary Togglebluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype First gene therapy recommended for approval in the EU for TDT Treatment with ZYNTEGLO has been shown to help eliminate the need for chronic blood transfusions in patients with TDT ZYNTEGLO is bluebird bio’s first gene therapy submitted for regulatory approval CAMBRIDGE, Mass.
03/25/19
Summary Togglebluebird bio Statement on European Regulatory Status of LentiGlobin™ CAMBRIDGE, Mass.--( BUSINESS WIRE )--A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of
03/22/19
Summary Togglebluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina Gov. Cooper to cut ribbon on facility that will strengthen bluebird bio's capabilities to manufacture products for clinical development and commercial supply CAMBRIDGE, Mass. & DURHAM, N.C. --(BUSINESS WIRE)--Mar. 22, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the official opening of
03/08/19
Summary Togglebluebird bio to Present at Investor Conferences in March CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 8, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Cowen and Company 39 th Annual Health Care Conference , Tuesday, March 12 , at 8:40 am ET at the
02/21/19
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress - Strong 2018 marked by the company’s first European Marketing Authorization Application for LentiGlobin in transfusion-dependent β-thalassemia (TDT) – - Data across LentiGlobin studies in TDT and sickle cell disease (SCD) and bb21217 in multiple myeloma presented at American Society of Hematology
02/11/19
Summary Togglebluebird bio Appoints Chip Baird as Chief Financial Officer CFO with proven track record will help lead transition to commercial company Jeff Walsh to assume role of chief strategy officer Jason Cole to assume role of chief operating and legal officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 11, 2019-- bluebird bio, Inc .
01/07/19
Summary Togglebluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies CAMBRIDGE, Mass. & SAN DIEGO --(BUSINESS WIRE)--Jan. 7, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) and Inhibrx, Inc. (Inhibrx) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using
01/03/19
Summary Togglebluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 37 th Annual J.P. Morgan Healthcare Conference , Tuesday, January 8 , at 2:30 p.m. PT at the Westin St.

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.